STOCK TITAN

Anaptysbio Inc SEC Filings

ANAB NASDAQ

Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing AnaptysBio’s dense immunology disclosures can feel like decoding a scientific journal. When the annual report 10-K stretches past 300 pages and each 8-K material event carries pipeline-moving details, locating what matters about somatic hyper-mutation spending or milestone revenue is time-consuming.

Stock Titan solves that problem. Our AI-powered summaries turn every AnaptysBio quarterly earnings report 10-Q filing and AnaptysBio insider trading Form 4 transactions into plain-English highlights—no more search-and-scroll. Receive real-time alerts the moment AnaptysBio Form 4 insider transactions real-time hit EDGAR, and let our platform surface context-rich charts that explain R&D burn, cash runway, and collaboration economics. Curious about executive pay? The AI links directly to the AnaptysBio proxy statement executive compensation sections you need.

Here’s what investors gain:

  • 10-K simplified – critical risk factors, antibody pipeline updates, and patent positions extracted for quick review (AnaptysBio annual report 10-K simplified).
  • 10-Q analysis – quarter-over-quarter shifts in R&D expense and partnership revenue with instant AnaptysBio earnings report filing analysis.
  • Form 4 drill-downs – see every AnaptysBio executive stock transactions Form 4 alongside historical price charts.
  • 8-K alerts – material trial results or collaboration amendments appear under “AnaptysBio 8-K material events explained”.

Whether you’re understanding AnaptysBio SEC documents with AI for the first time or monitoring repeat insiders, Stock Titan delivers the transparency you need—faster than toggling through EDGAR links.

Rhea-AI Summary

Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025. The filing details:

  • Sale of 3,015 shares of Common Stock at $23.97 per share
  • Transaction was executed under a Rule 10b5-1 trading plan established on March 22, 2024
  • The sale was primarily to satisfy tax obligations related to restricted stock unit vesting on June 15, 2025
  • Following the transaction, Fenton retains direct ownership of 4,965 shares

This transaction appears to be a planned sale for tax purposes rather than a discretionary trade, as evidenced by the pre-established 10b5-1 plan. The sale represents a partial liquidation of Fenton's holdings, maintaining a significant ownership position in the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Director Hollings Renton of AnaptysBio reported a sale of 3,015 shares of common stock at $23.97 per share on June 18, 2025. Following the transaction, Renton retains direct ownership of 4,965 shares.

Key details of the transaction:

  • The sale was executed under a Rule 10b5-1 trading plan established on March 14, 2024
  • The shares were sold to cover tax obligations related to the vesting of restricted stock units on June 15, 2025
  • Total transaction value: approximately $72,269

This insider transaction represents a routine sale for tax purposes rather than a discretionary trading decision, as it was pre-planned through a 10b5-1 trading plan and specifically tied to RSU vesting obligations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

AnaptysBio (NASDAQ:ANAB) filed a routine Form 144 on June 29, 2025, notifying the SEC of a proposed sale of 3,015 common shares valued at approximately $72,269.55 (about $23.96 per share). The shares were originally received as restricted stock on June 15, 2025 and are expected to be sold around June 18, 2025 through Morgan Stanley Smith Barney. The filer reported no other sales in the past three months and affirmed that no undisclosed material adverse information is known. With 29,380,496 shares outstanding, the proposed sale represents a negligible fraction of total equity and does not indicate any material change to AnaptysBio’s operations or financial condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Filing
Rhea-AI Summary

Safe and Green Development Corporation (Nasdaq: SGD) filed a Form 8-K to disclose an Amendment to a Balloon Payment Promissory Note originally issued on 15 Nov 2024 to Pigmental LLC. The note’s outstanding principal remains $960,672. Under the revised terms, SGD has already received an $40,000 earnest-money payment. The borrower must deliver a second installment of $250,000 on or before 30 Jul 2025 (with a discretionary 30-day extension) and a final payment of $670,672 on or before 30 Oct 2025 (extension to 29 Nov 2025 if the second payment is deferred).

The amendment strengthens lender protections through:

  • Automatic acceleration of all amounts due if any scheduled payment is missed.
  • Cross-default for obligations exceeding $50,000.
  • Default upon material adverse change in the borrower’s financial condition.
  • Default for failure to perfect security interests.
The full amendment is filed as Exhibit 99.1.

No equity issuance, business combination, or earnings data were included. The disclosure is routine but provides clarity on expected cash inflows and tighter credit terms designed to mitigate counter-party risk.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Anaptysbio (ANAB)?

The current stock price of Anaptysbio (ANAB) is $22.2 as of June 30, 2025.

What is the market cap of Anaptysbio (ANAB)?

The market cap of Anaptysbio (ANAB) is approximately 670.5M.

What is the core focus of AnaptysBio Inc?

AnaptysBio Inc focuses on developing innovative antibody therapeutics using its proprietary somatic hypermutation platform. The company targets unmet medical needs in autoimmune and inflammatory diseases through precision-engineered antibodies.

How does the shm-xel platform work?

The shm-xel platform replicates the natural process of antibody maturation by inducing somatic hypermutation in vitro within mammalian cells. This enables the optimization of antibody properties such as high affinity, specificity, and manufacturability.

Which therapeutic areas is AnaptysBio addressing?

The company is active in addressing a range of conditions including autoimmune disorders, inflammatory diseases, and immuno-oncology indications. Its pipeline includes candidates for rheumatoid arthritis, ulcerative colitis, atopic dermatitis, and other related diseases.

What differentiates AnaptysBio from other biotech firms?

AnaptysBio distinguishes itself through its unique use of in vitro somatic hypermutation technology and its targeted approach to antibody discovery. This technological innovation, combined with strategic partnerships, enables the development of differentiated therapeutic candidates.

How does the company generate revenue?

Revenue is generated through a combination of strategic licensing arrangements, collaborative partnerships with larger pharmaceutical companies, and milestone-driven financial collaborations. These structures support both clinical development and commercialization efforts.

What is the significance of the company’s clinical-stage pipeline?

The clinical-stage pipeline is a testimony to AnaptysBio’s scientific rigor and innovation. It reflects comprehensive research and development efforts aimed at delivering novel, immune cell modulators and cytokine antagonists to meet critical therapeutic needs.

How do strategic partnerships enhance AnaptysBio’s operations?

Strategic partnerships facilitate non-dilutive funding, provide access to advanced research and development resources, and bolster commercialization efforts. Such collaborations validate the clinical potential of key programs and reinforce the company’s market position.

What kind of scientific expertise does AnaptysBio bring to the biotechnology field?

AnaptysBio leverages extensive expertise in antibody engineering, immunology, and clinical research. Its commitment to replicating natural immune processes and rigorous clinical evaluation demonstrates deep industry knowledge and methodological precision.
Anaptysbio Inc

NASDAQ:ANAB

ANAB Rankings

ANAB Stock Data

670.46M
27.86M
4.41%
121.92%
29.45%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO